



Published in final edited form as:

Metab Eng. 2018 September ; 49: 94–104. doi:10.1016/j.ymben.2018.07.013.

Development of a cyanobacterial heterologous polyketide production platform

Julia Roulet¹, Arnaud Taton², James W. Golden², Ana Arbolaza^{1,*}, Michael D. Burkart^{3,*}, and Hugo Gramajo¹

¹Microbiology Division, IBR (Instituto de Biología Molecular y Celular de Rosario), Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Ocampo y Esmeralda, 2000 Rosario, Argentina.

²Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.

³Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA.

Abstract

The development of new heterologous hosts for polyketides production represents an excellent opportunity to expand the genomic, physiological, and biochemical backgrounds that better fit the sustainable production of these valuable molecules. Cyanobacteria are particularly attractive for the production of natural compounds because they have minimal nutritional demands and several strains have well established genetic tools. Using the model strain *Synechococcus elongatus*, a generic platform was developed for the heterologous production of polyketide synthase (PKS)-derived compounds. The versatility of this system is based on interchangeable modules harboring promiscuous enzymes for PKS activation and the production of PKS extender units, as well as inducible circuits for a regulated expression of the PKS biosynthetic gene cluster. To assess the capability of this platform, we expressed the mycobacterial PKS-based mycocerosic biosynthetic pathway to produce multimethyl-branched esters (MBE). This work is a foundational step forward for the production of high value polyketides in a photosynthetic microorganism.

Keywords

Cyanobacteria; Heterologous production; PKS-derived compounds; Synthetic Biology

*Corresponding author(s): arabolaza@ibr-conicet.gov.ar, mburkart@ucsd.edu.

Author contributions

J.R., A.T., A.A., M.D.B., and H.G. designed the research; J.R. and A.T. performed the experiments; J.R., A.T., A.A., M.D.B., and H.G. analyzed the data; J.R., A.T., A.A., and H.G. wrote the manuscript. M.D.B. and J.W.G. reviewed and edited the manuscript. All authors read and approved the manuscript.

Competing financial interests

J.R., A.T., J.W.G., A.A., M.D.B., and H.G. are authors on a patent application entitled “Engineering polyketide synthase machinery in cyanobacteria”; U.S. Provisional Application Serial No. 62/643,370 filed on March 15, 2018.

1. Introduction

Polyketides are included in a large family of natural products that possess a wide variety of relevant pharmacological and biological activities. Numerous polyketides and their semisynthetic derivatives have been approved for clinical use in humans and animals, including antibiotics, antifungal agents, immunosuppressants, antiparasitic agents, and insecticides¹. All these natural products share a common mechanism of biosynthesis and are produced by a class of enzymes called polyketide synthases (PKSs). These enzymes condense and reduce a small series of simple 2-, 3-, and 4-carbon acyl groups derived from coenzyme A (CoA) thioesters (for example malonyl-CoA, methylmalonyl-CoA, and ethylmalonyl-CoA) to build the polyketide backbone in a step-wise manner that resembles fatty acid biosynthesis². Besides their essential role in the biosynthesis of a vast diversity of natural products, the versatility of PKSs can be further emphasized as they can be redesigned and repurposed to produce novel molecules that could be used as fuels, industrial chemicals, and monomers^{1,3-8}.

Most polyketide producers are slow-growing, recalcitrant to genetic manipulation, or even non-culturable^{2,9}. Therefore, as an alternative to studying these polyketides and their encoding gene clusters from the native producers, the heterologous production of polyketide molecules has proven to be a valuable strategy. Since its early days^{10,11}, the heterologous expression of the PKS biosynthetic gene clusters has greatly facilitated our understanding of the basic enzymatic mechanisms involved in polyketide biosynthesis and enabled the manipulation of polyketide-encoding pathways either to improve their production or in order to generate novel molecules with novel properties^{1,8,12-15}.

Photosynthetic microorganisms are attractive platforms for the production of specialty chemicals, valuable drugs, and fuels because they can use CO₂ and sunlight as sole sources of carbon and energy¹⁶. Cyanobacteria are the only prokaryotes that can perform plant-like oxygenic photosynthesis. In comparison to eukaryotic algae, several strains of cyanobacteria have facile genetics that take advantage of their natural competency to take up exogenous DNA and their capability to integrate DNA into their chromosome through homologous recombination. In this regard, *Synechococcus elongatus* strain PCC 7942 (thereafter *S. elongatus*) is an excellent host strain that grows rapidly and segregates mutations efficiently. *S. elongatus*'s fundamental biological processes and primary metabolism have been extensively studied¹⁷⁻¹⁹. In addition, genome-scale metabolic models, as well as a broad array of advanced genetic tools, facilitate the engineering and construction of complex metabolic systems²⁰⁻²². *S. elongatus* and other cyanobacteria have been used as photosynthetic biocatalysts for the biosynthesis of several industrial compounds²³⁻²⁵. However, synthetic biology and metabolic engineering of cyanobacteria have only rarely been applied to natural product pathways^{26,27}.

In this work, we demonstrate the potential of the photosynthetic microorganism *S. elongatus* as a versatile platform for the heterologous biosynthesis of PKS-derived molecules. To facilitate the construction of diverse recombinant cyanobacteria, we developed a modular design where each module comprises a set of enzymes that perform a specific function required for the biosynthesis of the final polyketides and polyketide-like molecules. As a

proof of concept, we focus on the type I iterative *Mycobacterium tuberculosis* PKS MAS system (comprising *mas*, *papA5*, *fadD28* genes) and show that the engineered *S. elongatus* strains produce (2S)-methylmalonyl-CoA PKS-derived molecules.

2. Materials and Methods

2.1. Strain construction and culture conditions

Plasmid DNA was introduced by natural transformation in a sub-strain of *S. elongatus* PCC 7942 (AMC2302), which was cured of its small plasmid, pANS^{28,29}. Recombinant DNA harboring the functional modules I through III (Fig. 1) and an antibiotic resistance gene were integrated into the chromosome at neutral site 1 (NS1), 2 (NS2), and 3 (NS3) or were carried on self-replicating plasmids based on the native pANS plasmid of *S. elongatus* PCC 7942^{21,29,30}. Plasmids and cyanobacterial strains constructed in this study are listed in Table 1 and 2, respectively. *S. elongatus* strain AMC2302 was grown in BG11 medium³¹ as 50-ml or 100-ml cultures at 30°C with continuous shaking or on agar plates (40 ml, 1.5% agarose) and continuous illumination of 150- $\mu\text{mol photons m}^{-2} \text{s}^{-1}$. Media were supplemented with appropriate antibiotics at the following final concentrations: 2 $\mu\text{g/ml}$ each spectinomycin (Sp) and streptomycin (Sm), 2 $\mu\text{g/ml}$ gentamycin (Gm), 5 $\mu\text{g/ml}$ kanamycin (Km), and 10 $\mu\text{g/ml}$ nourseothricin (Nt).

E. coli strains were grown at 37°C with LB medium in tubes placed on a roller drum, or on agar plates supplemented with appropriate antibiotics at standard concentrations.

2.2. General methods for vector and plasmid assembly

Plasmid preparations were carried out with QIAprep Spin Miniprep Kit (Qiagen). Restriction digests were typically performed for 3 to 5 h, using 5U of enzyme per pg of plasmid DNA in a final volume at least 50 times greater than the volume of the enzyme added. PCR amplifications were carried out with Q5 enzyme (New England BioLabs) according to the manufacturer's instructions. DNA purification and concentration of restriction digests and PCR products were performed with DNA Clean & Concentrator TM-5 (Zymo). Nucleic acid concentrations were measured with a UV-Vis spectrophotometer NanoDrop 2000c. Cloning reactions were performed by Gibson assembly using GeneArt Seamless Cloning and Assembly Kit (Life Technologies).

Vector backbones were constructed *in silico* using the CYANO-VECTOR portal <http://golden.ucsd.edu/CyanoVECTOR/> then assembled from compatible devices as described previously²¹. Briefly, DNA devices including *S. elongatus* recombination or replicon sequences, *E. coli* origin of replication, antibiotic selection markers and expression cassettes were released from donor plasmids by restriction digests using Zral or EcoRV-HF (New England BioLabs). Then, assembly reactions were carried out using equimolar ratios of each device adjusted to a final concentration of about 8 ng/ μl . To obtain final constructs, inserts were either obtained by PCR, or synthesized and then assembled into vector backbones linearized by restriction digests.

Intermediate plasmids and destination vectors, and primer sequences used in this work are listed in the Supplementary Table S1 and Table S2, respectively. Details on the construction

of each plasmid developed for the platform are provided as supplementary material (Fig. S1). The vectors were designed to be easily used for the exchange of different modules. Codon optimized synthetic gene sequence is detailed in Supplementary Materials and Methods. Synthetic DNA fragments were ordered as synthetic genes (GenScript) or gene blocks (SGI-DNA) and the *matB* gene was codon optimized using the COOL algorithm³²

2.3. Yellow Fluorescent Protein (YFP) fluorescence measurements

First, cyanobacterial strains were adjusted to an optical density at 750 nm (OD_{750}) of 0.2 and pre-grown for 48 h in liquid culture. Then, cultures were adjusted to OD_{750} of 0.1 before fluorescence measurements. For induction, 2-mL cultures were grown in 24-well plates and adjusted to final concentrations of 0, 0.25, 0.5, 1, 2 and 4 mM theophylline (Sigma-Aldrich). Theophylline was dissolved in DMSO at different stock concentrations (0, 25, 50, 100 and 200 mM) to obtain a final ratio of inducer solution to culture of 1% v/v or 2% v/v (for 4 mM theophylline). The plates were set on a shaker (125 rpm) at 30°C under continuous illumination of $100 \mu\text{mol photons m}^{-2} \text{s}^{-1}$ for 24 h. This time point was selected based in our previous work²², where we described and analyzed theophylline-responsive riboswitches. The optical densities and emission intensities of YFP were measured from 200 μL of culture in 96 well plates with a Tecan Infinite(R) M200 plate reader (TECAN). Black-walled 96 well plates (Greiner) were used to measure fluorescence intensities. The excitation and emission wavelengths were set to EX490/9 and EM535/20 for YFP. Measurements were taken from 2 or 3 independent strains and biological-triplicate cultures for each strain.

2.4. Phosphopantetheinyl Transferase (PPTase) *in vitro* assays

Soluble protein extracts from *S. elongatus* AMC2302 recombinant strains with a protein concentration of approximately 3 mg/mL were added to a volume of premade 10 \times PPTase reaction buffer (500 mM Na-HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic sodium salt) and 100 mM MgCl_2 , pH 7.6) that brought the total reaction concentration to 50 mM Na-HEPES, pH 7.6; 10 mM MgCl_2 ; 100 μM TAMRA (Carboxytetramethylrhodamine)-CoA; TCEP (Tris(2-carboxyethyl)-phosphine) 5 mM and *apo*-ACP 25 mM. In the positive control, 2 μM Sfp was added instead of the protein extracts of the recombinant strains. Samples were incubated at 37°C overnight and then the detection of the ACP phosphopantetheinylation was carried out on SDS-PAGE and the reporter-labeled ACP was visualized by UV fluorescence.

2.5. Bioconversion assays

The cyanobacterial strains were pre-grown in liquid cultures (with appropriate antibiotics) for 3 to 4 days prior to induction. Then, the cultures were adjusted to an OD_{750} of 0.4, and the theophylline inducer was added. These cultures were grown for 19 h while shaking at 30°C under continuous illumination at $150 \mu\text{mol photons m}^{-2} \text{s}^{-1}$, and then supplemented with the appropriate precursors (*n*-octanol and propionate or methylmalonate), and ¹⁴C-acetate (58.9 mCi/mmol, PerkinElmer) to label the products. All assays were performed in triplicate with independent strains. Samples were collected 48 h after the precursors were added, stored at -80°C and lyophilized before processing for TLC (Thin Layer Chromatography) analysis.

For the *E. coli* bioconversion assay, an overnight culture of the strain RQ1⁸ was used to inoculate fresh LB medium supplemented with 20 μ M biotin and the appropriate antibiotics. At mid-exponential phase, the culture was induced with 0.1 mM IPTG, and 30 mM propionate, 0.5 mM *n*-octanol, and ¹⁴C-acetate (58.9 mCi/mmol, PerkinElmer) label were added. The induced culture was incubated for 20 h at 22°C. Then, the sample was collected and total lipids were extracted according to the Bligh and Dyer method³³.

2.6. TLC analysis

Total lipid samples were extracted by the Bligh and Dyer method with minor modifications³³. First, the culture was lyophilized, then the cell pellet/lyophilized sample was resuspended in water. Subsequently, a solution of 1:2 chloroform: methanol with acetic acid 1% (final v/v) was added, and the samples were vortexed. Then chloroform and NaCl 1 M were added and finally centrifugated to separate phases. Total lipid extracts were analyzed by radio-TLC on silica gel 60 F254 plates (\pm 0.2 mm, Merck) using the solvent system hexane/diethyl-ether/acetic acid (90: 7.5: 1, v/v/v) for the mobile phase. The lipids were visualized by using a Typhoon Phosphorimager (GE Healthcare) and the spots corresponding to methyl-branched esters (MBEs) from the *S. elongatus* recombinant strains were assigned by R_f (Ratio of front) comparison with MBE synthesized by the *E. coli* RQ1 producer strain used as a standard⁸.

3. Results

3.1. Modules for the production of PKS-derived compounds

For a heterologous host to be suitable for the biosynthesis of PKS-derived compounds, it must be able to: 1) produce the appropriate PKS carboxyacyl-CoA substrates (extender units); 2) carry out the post-translational modification of the heterologous PKS ACP domain(s); and 3) harbor a robust and preferably regulated expression system for the often large and polycistronic PKS gene clusters. Therefore, we designed and constructed for *S. elongatus* three independent interchangeable and combinable modules (Fig. 1). Each module comprises a set of enzymes to perform the specific functions listed above. Module I is dedicated to the production of different carboxyacyl-CoAs used as PKS substrates. Module II includes T7 gene 1 (hereafter *T7RNAP*), which encodes the T7 RNA polymerase (T7 RNAP), for the robust and controlled expression of a PKS gene cluster driven by a T7 promoter (P_{T7}), and a promiscuous phosphopantetheinyl transferase (PPTase) for the post-translational modification of the PKS³⁴. Finally, module III harbors the PKS gene cluster driven by P_{T7}.

Considering that the biosynthesis of many industrially relevant polyketides needs malonyl-CoA, methylmalonyl-CoA and/or ethylmalonyl-CoA as substrates³⁵, three different pathways capable of generating these carboxyacyl-CoAs, but mainly focusing in methylmalonyl-CoA production, were designed as **Module I**. The first pathway involves *matB* from *Streptomyces coelicolor* and the epimerase (*epi*) gene from *Propionibacterium shermanii*. MatB is an acyl-CoA synthetase³⁶ with a relaxed substrate specificity that allows the *in vitro* synthesis of different PKS extender units such as malonyl-CoA, methylmalonyl-CoA, ethylmalonyl-CoA, hydroxymalonyl-CoA, and methoxymalonyl-CoA from the

Author Manuscript

corresponding carboxylic acid substrates³⁶. The broad substrate specificity of this enzyme would contribute to the versatility of the platform strain because it would enable the intracellular production of more than one PKS extender unit, depending on the exogenous supply of the carboxylic acid. Because PKSs recognize only the 2S isomer of the α -substituted carboxyacyl-CoAs, and considering that MatB produces a racemic mixture of them, the epimerization of (2R)- α -substituted extender units formed by MatB would increase the availability of the correct 2S isomer before it can be accepted by the PKS acyltransferase domains. In this sense, we decided to co-express the methylmalonyl-CoA epimerase (*epi*) from *P. shermanii*³⁷ to shift the equilibrium of the reaction towards the correct 2S isomer and therefore improve the production of the final polyketide. Hereafter this module will be named module IA (Fig. 1).

Author Manuscript

The second pathway for methylmalonyl-CoA production involves the sequential action of two enzymes, methylmalonyl-CoA mutase complex (*mutAB*) and methylmalonyl-CoA epimerase from *P. shermanii*, which convert succinyl-CoA to (2R)-methylmalonyl-CoA and then to (2S)-methylmalonyl-CoA³⁷. This biosynthetic route was designed as module IB (Fig. 1).

Author Manuscript

The third pathway involves the *S. coelicolor* propionyl-CoA carboxylase (PCC) complex, which comprises the AccA2, PccB, and PccE subunits³⁸. This enzyme complex has also been demonstrated to have a relaxed substrate specificity *in vitro*, being able to produce (2S)-methylmalonyl-CoA and (2S)-ethylmalonyl-CoA from their corresponding substrates, propionyl-CoA and butyryl-CoA, respectively³⁸. This module was named IC (Fig. 1). Because the PCC substrate, propionyl-CoA, is not readily available in most bacteria, the PCC biosynthetic route requires an exogenous supply of propionate, which has to be further converted into propionyl-CoA. We hypothesized that this latter step could be performed by the *S. elongatus* native acetyl-CoA synthetase/acetyl-CoA ligase (AcsA, SynPCC7942_1352) because its orthologous protein from *Synechococcus* sp. PCC 7002 showed *in vitro* CoA ligase activity towards various organic acids, including acetate and propionate³⁹.

Author Manuscript

The main genes of module I, namely MatB, MutAB complex, and the PCC complex, were cloned in a plasmid vector derived from *S. elongatus* small plasmid pANS (formerly identified as pUH24)⁴⁰ downstream of a synthetic *E. coli* promoter (P_{conII})^{21,41} (Table 1). We expected that placing these genes in a replicative vector and downstream of a constitutive, medium strength promoter⁴² should ensure high levels of gene expression and the availability of the precursor molecules. What is more, pANS vector can also replicate in *Anabaena* sp PCC 7120 that could be used as an alternative cyanobacterial host^{26,29}. The *epi* gene was also cloned downstream of P_{conII} but in an integrative vector that recombines into the neutral site NS2 on the *S. elongatus* chromosome (Table 1)³⁰.

Author Manuscript

Module II was designed to enable the orthogonal expression of the PKS biosynthetic gene cluster and the post-translational modification of the acyl carrier protein domain(s) (ACP) of the PKS. A variety of constitutive and inducible expression systems have been used in *S. elongatus*^{21,22,43-46}, but compared to many other applications, the expression of PKS gene clusters presents additional challenges. PKSs are often arranged as large polycistronic

transcriptional units, and although low levels of expression may be essential in some cases, several studies have suggested that the biosynthesis of polyketides and other bioactive specialized metabolites (at detectable levels) may require the use of strong promoters¹⁴. Therefore, we hypothesized that a controlled T7 expression system would be well suited for the expression of PKS gene clusters and could be engineered in *S. elongatus*. Typically, the gene encoding T7 RNAP is under the control of a derivative of the *lac* promoter, which is tightly regulated by the LacI repressor⁴⁷. IPTG inducible promoter systems have been used in cyanobacteria and in *S. elongatus* in particular; however, they usually exhibit high basal activity levels in the absence of inducer, and poor induction ratios^{22,44,48}. In comparison, theophylline-inducible riboswitches that control translation initiation provide tighter control of gene expression with higher induction ratios²². Therefore, for better control of the T7 RNAP expression, we constructed expression devices in which the transcription of the T7 RNAP was driven by two different variants of the *conII* promoter, while the translation of the T7 RNAP was controlled by theophylline-dependent riboswitches (see below).

For the post-translational modification of ACP domains within PKSs, a 4'-phosphopantetheinyl transferase (PPTase) activity is essential to catalyze the addition of the 4'-phosphopantetheine (PPant) moiety onto this domain to generate its active *holo* form^{34,49}. The *S. elongatus* genome does not encode PKS or non-ribosomal peptide synthase (NRPS) clusters^{50,51}. Although a Sfp-type PPTase was identified in its genome⁵², further characterization of this PPTase showed that it exhibits very low or no activity towards ACPs of different PKSs⁵². Therefore, as part of module II, we constructed a device in which the promiscuous Sfp-PPTase from *Bacillus subtilis*⁴⁹ was expressed from P_{conII} and placed under the translational control of riboswitch F (Fig. 1).

Module III is specifically dedicated to the enzymes involved in the biosynthesis of a final product. Here, we focused on the production of multimethyl-branched wax esters (MBE) using the PKS-based mycocerosic biosynthetic pathway (MAS) from *Mycobacterium tuberculosis*. The MAS pathway is naturally involved in the biosynthesis of the multimethyl-branched fatty acids that form part of the complex lipid phthiocerol dimycocerosate⁵³. The PKS MAS system has been previously repurposed for the production of multimethyl-branched wax esters (MBEs) in *E. coli*⁸. MBEs have been shown to have exceptional physicochemical properties as bio-lubricants¹². This system relies on the expression of FadD28 (acyl-AMP ligase), the PKS Mas (mycocerosic acid synthase), and PapA5 (polyketide-associated protein A5)⁸. The three coding sequences for these enzymes were cloned in an operon configuration downstream of P_{T7} (Fig. 1).

Modules II and III, specifically target neutral sites for chromosomal integration by homologous recombination in *S. elongatus* genome. Therefore, these modules are specific for *S. elongatus*. However, the neutral site could be replaced to be compatible with another strain of cyanobacteria²¹.

3.2. Development of theophylline-responsive T7 expression circuits

To establish a functional, inducible, and tightly regulated T7 RNAP-based expression circuit for *S. elongatus*, we initially constructed devices in which the transcription of the T7 RNAP was driven by P_{conII} and its translation was controlled by either the theophylline-dependent

riboswitches B or F^{22,46} The induction ratios of these riboswitches were previously evaluated in devices in which P_{conII} drove the expression of the *yfp* gene ($P_{\text{conII}}\text{-yfp}$)²². While riboswitch F enabled a higher level of expression after induction, riboswitch B provided tighter control with a lower uninduced level of expression²². Based on these studies we evaluated these regulatory parts to develop the regulated T7 RNAP expression circuits in *S. elongatus*.

To characterize the expression circuits, we constructed a reporter device in which the *yfp* gene was driven by P_{T7} ($P_{\text{T7}}\text{-yfp}$) and two devices in which the *T7RNAP* gene was placed under the control of the conII promoter and riboswitch F ($P_{\text{conII}}\text{-rswF-}T7RNAP$) or riboswitch B ($P_{\text{conII}}\text{-rswB-}T7RNAP$). The reporter device was integrated at NS2 on the *S. elongatus* chromosome³⁰. The *T7RNAP* expression device, either $P_{\text{conII}}\text{-rswF-}T7RNAP$ or $P_{\text{conII}}\text{-rswB-}T7RNAP$, was integrated at NS1 on the *S. elongatus* chromosome³⁰. Both expression circuits ($P_{\text{conII}}\text{-rswF-}T7RNAP/P_{\text{T7}}\text{-yfp}$ and $P_{\text{conII}}\text{-rswB-}T7RNAP/P_{\text{T7}}\text{-yfp}$) were then characterized in the *S. elongatus* strains by measuring YFP-fluorescence one day after addition of 2 mM theophylline or 1% DMSO vehicle control. In absence of the theophylline inducer, both circuits produced relatively high levels of the YFP reporter (high background). With the inducer, only a small increase or no increase of the YFP-fluorescence level was measured. These results indicated that neither of these two circuits was satisfactory for controlling gene expression in *S. elongatus*, but it is worth noting that the highest levels of YFP-fluorescence were produced by the strains in which the *T7RNAP* gene was placed under the control of $P_{\text{conII}}\text{-rswF}$ (data not shown).

In order to reduce the background levels of the T7 RNAP, we engineered a weakened version of P_{conII} to drive the *T7RNAP* expression. This targeted mutation in the -10 sequence of P_{conII} (indicated as P_{conII}^*) led to significantly lower basal levels of uninduced YFP fluorescence in strains containing either of the two riboswitches. As shown in Fig. 2, the two new *T7RNAP* expression devices controlled by $P_{\text{conII}}^*\text{-rswB}$ or $P_{\text{conII}}^*\text{-rswF}$ produce a clear dose-dependent response to the theophylline inducer (Fig. 2). Although the highest levels of YFP expression were similar with both riboswitches F and B, lower concentrations of theophylline (1 mM compared to 2 mM) were needed for the riboswitch F to reach maximal expression. On the other hand, riboswitch B showed a tighter control in the absence of the inducer (Fig. 2). Note that under the low-density growth conditions of these strains for this experiment, a concentration of 4 mM theophylline produced lower YFP expression presumably due to some theophylline toxicity²².

We chose to continue our studies with two of the T7 RNAP expression devices: 1) the original P_{conII} and riboswitch F device, which did not show theophylline regulation but produced the highest levels of expression and 2) the mutated P_{conII} (P_{conII}^*) and riboswitch B device, which enabled a tighter control of the T7 RNAP and allows testing of different expression levels. We chose the first expression device because we assumed that in some cases the production of polyketides may be limited by the levels of their biosynthetic enzymes. Therefore, having higher expression levels of the MAS pathway would give us a better chance of detecting MBE production in cyanobacteria. These expression devices were used in the construction of modules IIA and IIB (Fig. 1).

3.3. Analysis of protein expression in recombinants *S. elongatus*

Using our synthetic biology tools for cyanobacteria²¹, we assembled the functional modules (Fig. 1) into appropriate plasmid vectors. Details on each plasmid developed for the platform are presented in Supplementary Fig. 1 and their construction is described in Supplementary Methods. The recombinant cyanobacterial strains described in Table 2 were obtained by sequential transformation with the indicated recombinant vectors. Each of the final six recombinant strains that were constructed carried a different combination of the functional modules I, II, and III.

The heterologous proteins that are involved in the biosynthesis of methylmalonyl-CoA (Module I) including MatB, the MutA subunit, and the epimerase were FLAG-tagged for western blot analyses. These assays indicated that MutA was not expressed with the correct size in some *S. elongatus* strains and in others strains it was not expressed at detectable levels (Supplementary Fig. 2), consequently we did not pursue any further development of these strains. On the other hand, MatB and the epimerase were expressed with the expected molecular weights on western blots (Supplementary Fig. 2). The PccB subunit of the PCC complex was analyzed with a specific anti-PccB antibody³⁸ and showed correct expression (Supplementary Fig. 3). The three enzymes of the PKS pathway, PapA5, FadD28, and Mas, were His-tagged and were detected as soluble proteins in the cyanobacterial strains by western blot analyses (Supplementary Fig. 4). These results showed that *S. elongatus*, which does not have PKS and NRPS genes in its genome^{50,51}, is capable of expressing the proteins for a complex heterologous pathway including the Mas protein, which is a large multidomain PKS enzyme. In addition, the fact that the MAS pathway was expressed in all of the recombinant cyanobacterial strains analyzed also indicates that both T7 RNAP expression devices constructed and tested here can successfully drive the expression of the genes cloned in module III.

3.4. Functional analysis of phosphopantetheinyl transferase

To determine Sfp expression and functional activity in *S. elongatus*, we employed an assay for the addition of the fluorescently labeled pantetheine analogue (TAMRA-CoA) to the type II *E. coli* fatty acid synthase ACP (AcpP)⁵⁴. Soluble protein extract from each recombinant cyanobacterium containing the heterologous Sfp enzyme or from *S. elongatus* wild-type strain AMC2302 was added to recombinant apo-AcpP in the presence of TAMRA-CoA. The detection of the ACP phosphopantetheinylation was carried out on SDS-PAGE; and the reporter-labeled ACP was visualized by UV fluorescence (Fig. 3 and Supplementary Fig. 5). As shown in Fig. 3 and Supplementary Fig. 5, soluble protein extracts from the recombinant cyanobacterial strains pursued in this study allowed the conversion of *E. coli* ACP to its fluorescently labeled derivative. These results indicate that *S. elongatus* wild-type strain AMC2302 does not exhibit promiscuous native PPTase activity, as was previously reported⁵², and that the heterologous Sfp is expressed in its active form in all the *S. elongatus* recombinant strains analyzed. Therefore, considering that we had previously shown that the Mas synthase is a suitable substrate for Sfp^{8,55}, we were confident that the Mas enzyme would also be adequately phosphopantetheinylated in the recombinant strains here developed.

3.5. Production of PKS-derived MBE by *S. elongatus*

After the expression of the key proteins encoded by functional modules I, II, and III was confirmed, we further analyzed these strains for the production of MBE. Bioconversion assays were performed on four different strains: JR101 (modules IA + IIA + III), JR102 (modules IA + IIB + III), JR107 (modules IC + IIA + III), and JR108 (modules IC + IIB + III).

While module I was constitutively expressed from P_{conII} , the expression and activation of module III depended on the expression of the T7 RNAP and Sfp placed downstream of P_{conII} (or P_{conII^*}) and under the translational control of a theophylline-inducible riboswitch (F or B). The biosynthesis of (2S)-methylmalonyl-CoA required methylmalonate (module IA) or propionate (module IC) as substrates, and the transesterification of the PKS-ACP-bound multimethyl-branched fatty acid (MBFA) required an alcohol substrate *n*-octanol to produce MBE as the final product. Cell toxicity analyses with methylmalonate, propionate, and *n*-octanol were carried out to determine the optimal concentration of these precursors in the cyanobacterial cultures (Supplementary Fig. 6).

We first analyzed the two strains containing module IA (MatB and epimerase) for (2S)-methylmalonyl-CoA biosynthesis, modules IIA or MB for T7 RNAP and Sfp expression, and module III for the Mas and accessory enzymes expression. In addition, strains without module III and a wild-type strain were included as negative controls. For bioconversion assays the strains were induced with 2 mM theophylline and after 24 h supplemented with 10 mM methylmalonate, 0.25 mM *n*-octanol, and 2 μCi ^{14}C -acetate (58.9 mCi/mmol, PerkinElmer) to label the products. We used ^{14}C -acetate as an easy, sensitive and quick method for analyzing *de novo* lipids biosynthesis. *S. elongatus* is an obligate autotrophic microorganism and it strictly depends upon the generation of photosynthetically derived energy for growth, therefore ^{14}C -acetate was not used as an energy source for the microorganism. After addition of the precursors, the cultures were grown for 48 h, and the *in vivo* synthesis of MBE was analyzed in total lipid extracts from each culture by TLC fractionation and autoradiography (Fig. 4b and 4c). Additional bioconversion assays were carried out as controls where one or both precursors (methylmalonate and *n*-octanol) were absent. Labeled MBE obtained through a bioconversion assay using the *E. coli* strain RQ1 was used as a standard⁸.

The results of Fig. 4 clearly indicate that *S. elongatus* was successfully engineered to synthesize MBE. The production of MBE was indeed detected only when both precursors and all the enzymes of the MAS pathway (module III) were present. To confirm the identity of the putative MBE compounds, analytical characterization of purified MBE was carried out by LC-MS/MS experiments as detailed in Supplementary Methods (Supplementary Fig. 7). From this analysis, we conclude that MBE synthesized by *S. elongatus* recombinant strains are formed by the esterification of the MBFA derived from four iterative MAS-catalyzed extension steps of a C16:1 fatty acid and the *n*-octanol as acceptor alcohol. These results also indicate that (2S)-methylmalonyl-CoA is synthesized through the MatB-epimerase pathway (module IA) using methylmalonate as precursor. These assays further confirmed that both modules II (A and B) produce functional T7 RNAP and PPTase, which enable the expression and activation of module III enzymes. Finally, these findings indicate

that the MAS biosynthesis system (PapA5-FadD28-Mas) cloned as module III is properly expressed and functional in *S. elongatus*. Next, we sought to test module 1C for the biosynthesis of (2S)-methylmalonyl-CoA from propionate by the PCC pathway. This biosynthetic route was considered more challenging because it required the expression of a complex of three different subunits (AccA2, PccB, and PccE), and an exogenous supply of propionate, previously reported as toxic for *S. elongatus* at low concentrations³⁹, for conversion into propionyl-CoA. As mentioned earlier, we hypothesized that this enzymatic step could be performed by the *S. elongatus* native acetyl-CoA synthetase/acetate-CoA ligase (AcsA, SynPCC7942_1352). Preliminary analyses indicated that at a final concentration of 1 mM, propionate was not toxic for *S. elongatus* (Supplementary Fig. 6a). The bioconversion assays and MBE production analyses for JR107 and JR108 strains (as well as a wild-type strain as negative control) were performed as described above, but the cultures were adjusted to final concentrations of 1 mM propionate, 0.25 mM *n*-octanol, and 2 μ Ci ¹⁴C-acetate label (58.9 mCi/mmol, PerkinElmer). The results shown in Fig. 5 indicate that module IC for (2S)-methylmalonyl-CoA biosynthesis in cyanobacteria is also functional and enables MBE production.

The analysis of TLCs shown in Figures 4 and 5 and LC-MS/MS experiments (Supplementary Fig. 7) demonstrate that strains JR101 (modules IA + IIA + III), JR102 (modules IA + IIB + III), JR107 (modules IC + IIA + III), and JR108 (modules IC + IIB + III) produced (2S)-methylmalonyl-CoA PKS-derived MBE. These results provide evidence that (2S)-methylmalonyl-CoA is synthesized *in vivo* through both pathways (MatB-epimerase and PCC) and that (2S)-methylmalonyl-CoA is available as a substrate for the multidomain Mas PKS enzyme.

3.6. Effect of inducer concentration and MBE production

In order to study the response of the two selected regulatory modules IIA ($P_{\text{conII-rswF-sfp}}$ - $P_{\text{conII-rswF-T7RNAP}}$) and IIB ($P_{\text{conII-rswF-sfp}}$ - $P_{\text{conII*-rswB-T7RNAP}}$) at different concentrations of theophylline and determine their effect on MBE production, we carried out bioconversion assays with the strains JR101 and JR102 induced with a range of theophylline concentrations (0, 0.5, 1, 2, 4, and 8 mM). The TLC analyses showed that the production of MBE responded to the addition of the inducer in a concentration-dependent manner in both strains analyzed (Fig. 6). Similar to the results found with the T7 RNAP driving the YFP reporter, module IIB showed a tight inducer-dependent response in the strain JR102, and MBE levels were dependent on the concentration of the theophylline inducer up to 8 mM. Surprisingly, MBE production in the strain harboring module IIA also showed a dose-dependent response, however this regulation showed less MBE production at lower concentrations of theophylline and maximum MBE production at 4 mM theophylline with a decrease in MBE at 8 mM. This result suggests that the highest levels of expression of module III was detrimental for MBE production for unknown reasons. MBE production depends on the expression levels of the MAS pathway and other factors such as the Mas/Sfp ratio, the availability of the MBE precursors, and the general fitness of the strains. Obtaining maximum MBE production will require balancing all of these factors, which will be facilitated by the modular design utilized in this work.

4. Discussion

A wide variety of polyketide compounds are synthesized from a small subset of starter units such as acetyl-CoA and propionyl-CoA, and elongated with a specific subset of α -carboxyacyl-CoAs, which mainly include malonyl-CoA, (2S)-methylmalonyl-CoA, and (2S)-ethylmalonyl-CoA. Therefore, a robust heterologous platform for polyketide production must be endowed with the ability to synthesize these substrates. Because *S. elongatus* carries the metabolic pathways for the biosynthesis of acetyl-CoA and malonyl-CoA, but not for (2S)-methylmalonyl-CoA, which is the major extender unit used by PKSs after malonyl-CoA³⁵, we focused on the heterologous production of (2S)-methylmalonyl-CoA. For this, we selected enzymes that are able to synthesize (2S)-methylmalonyl-CoA, but that due to their substrate tolerance would also enable the orthogonal production of malonyl-CoA or of other PKS extender units, such as (2S)-ethylmalonyl-CoA, providing that the cells are fed with the proper substrate. Different pathways are responsible for the biosynthesis of (2S)-methylmalonyl-CoA in bacteria^{2,35}. Considering that the expression of recombinant genes depends upon multiple factors, in particular the heterologous host^{9,14,56}; and the fact that not all (2S)-methylmalonyl-CoA biosynthetic pathways are energetically or kinetically equivalent, we evaluated three alternative modules (IA, IB, and IC) to produce the PKS α -carboxyacyl-CoA substrates from three different heterologous pathways: MatB-epimerase, MutAB-epimerase, and PCC. The *in vivo* biosynthesis of (2S)-methylmalonyl-CoA by the PCC and MatB routes in the engineered strains of *S. elongatus* was confirmed by the production of the final MBE product (Fig. 4, 5, and Supplementary Fig. 7). Additional experimentation will be required to determine the full potential and versatility of our *in vivo* heterologous production platform by determining if the PCC and MatB routes produce all the expected carboxyacyl-CoA precursors that were previously produced *in vitro*^{36,38}. In addition, future work to enable the production of (2S)-methylmalonyl-CoA using the MutAB pathway in *S. elongatus* could prove to be useful, because we expect that its substrate could be endogenously produced in *S. elongatus*. However, recent genome scale metabolic predictions together with data on gene essentiality²⁰ showed the presence of a linear, noncyclic TCA pathway in *S. elongatus*, with no evidence of succinyl-CoA as intermediate. Therefore, because MutAB's substrate is succinyl-CoA, a succinyl-CoA synthetase would likely need to be co-expressed in the production strain. We also note that pANS-based shuttle vectors, where the genes of module I were cloned, also replicate stably in the filamentous cyanobacterium *Anabaena sp.* strain PCC 7120²⁹. Therefore, the biosynthesis of (2S)-methylmalonyl-CoA could be tested in *Anabaena* PCC 7120, which has a larger genome and several specialized metabolic pathways^{50,51}, and could be a more appropriate heterologous host for the production of some polyketides.

In order to develop a strong and regulated system of expression to drive the transcription of the polyketide biosynthetic genes, we developed T7 RNAP expression circuits for *S. elongatus*. We constructed four different expression devices where the *T7RNAP* was transcribed from two promoters with distinct strengths, P_{conII} or a weaker P_{conII}^* variant, and translated under the control of one of two theophylline-inducible riboswitches, each with different regulatory properties. Each of the four devices was characterized in *S. elongatus* strains carrying a reporter device where a *yfp* reporter gene was expressed from a

T7 promoter and YFP fluorescence served as the output (Fig. 2). For MBE production, two of the T7 RNAP expression devices were selected based on the highest levels of YFP expression (module IA) and tighter regulation of YFP expression (module MB). Characterization of the two different regulatory modules IIA and MB in *S. elongatus* (also containing modules I and III) showed that both IIA and MB were able to regulate the expression of the PKS genes, and therefore MBE production, in a dose dependent fashion (Fig. 6).

Considering that different polyketide biosynthetic pathways and/or their intermediates or final products may adversely affect the cells, and in order to cope with the variability and complexity of natural products and their biosynthetic pathways, it is important to create tunable expression circuits. The versatility of the two modules tested in this work indicates that the four T7RNAP expression devices would be well suited for heterologous expression of PKS gene clusters in *S. elongatus*. Moreover, other combinations of new P_{conII} mutants and different riboswitch variants²² could be generated and replaced in module II in order to adjust the expression of different PKS systems. In addition, the T7 promoter itself could be modified in order to fine tune the expression of the PKS cluster in module III⁵⁷.

Compared to heterotrophic microorganisms, the use of photosynthetic cyanobacteria as production platforms for chemicals is still in its infancy, and with the growing interest of using cyanobacteria for producing a wide variety of compounds, new genetic tools are essential. The T7RNAP-based expression circuits developed here are a valuable addition to the collection of genetic tools available for *S. elongatus*^{21,22,44,46}.

Specialized natural product pathways, in particular PKS and NRPS, invariably rely on the post-translational modification of the synthases to produce active enzymes. Because *S. elongatus* lacks a PPTase with activity towards the carrier proteins of different PKSs or NRPSs⁵², a promiscuous PPTase enzyme⁴⁹ was included in our platform strain, and *in vitro* assays confirmed that the enzyme was active (Fig. 3 and Supplementary Fig. 5). Because *S. elongatus* lacks any PKS or NRPS biosynthetic pathways^{50,51}, the engineering of a promiscuous PPTase activity into this strain provides a suitable platform with a clean background where heterologous production of PKS or NRPS derived molecules are less likely to face crosstalk, contamination, or competition from native pathways.

The heterologous expression of biosynthetic gene clusters in a photosynthetic microbial host that has minimal growth requirements and is amenable to genetic manipulations provides a powerful approach for exploring natural products from uncultivable organisms and metagenomic sequences. These heterologous production platforms can also be used to genetically modify biosynthetic pathways to produce novel products and for renewable large-scale production of a wide variety of compounds. These include medicines, biofuels, and polymer precursors¹. In this work, we demonstrated that the expression of a heterologous PKS pathway as well as its precursor biosynthetic pathways can result in functional enzymes and the production of the expected final compound in a photosynthetic microorganism. While the production of MBE by *S. elongatus* stands as a proof of concept, the platform strain, along with the synthetic biology tools that we have developed, provide a starting point for the production of a wide array of polyketide compounds. The modular

design of the platform described in this work will facilitate the optimization of polyketide production. Using the platform strains currently available, other (2S)-methylmalonyl-CoA derived polyketides could be produced in a sustainable manner by changing the third module with the desired PKS. Furthermore, this work suggests that production of other classes of PKSs that require malonyl-CoA, (2S)-ethylmalonyl-CoA, or other CoA precursors should also be achievable by following the same strategy.

5. Conclusion

Traditionally, the idea of heterologous production has stemmed from the desire to produce a known natural compound from elucidated pathways. However, with the advances of genome sequencing and bioinformatics, many new natural product pathways have been discovered^{58–61}. The overwhelming number of enigmatic biosynthetic gene clusters, coupled with the limitations associated to their study in native hosts, strongly supports the development of novel heterologous production platforms. This work provides a sustainable organism with an optimized genetic background for the interrogation of the wealth of biosynthetic gene clusters for specialized metabolites with known or unknown functions, and for synthetic biology approaches to manipulate or modify those pathways.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by Bec.AR-Fulbright fellowship to J.R., Y-TEC/ANPCyT grant PID-2013-0042 to H.G. and the National Institutes of Health NIH grant 5R01GM118815 to J.W.G. We thank Susan S. Golden for providing additional lab support, Jeffrey T. Mindrebo, Eunice Kim, Ryan Simkovsky, Brian P. Tieu, Cigdem Sancar, and Nathan Moss for research materials and technical support.

References

1. Yuzawa S, Keasling JD & Katz L Bio-based production of fuels and industrial chemicals by repurposing antibiotic-producing type I modular polyketide synthases: Opportunities and challenges. *J. Antibiot. (Tokyo)* 70, 378–385 (2017). [PubMed: 27847387]
2. Pfeifer BA & Khosla C. Biosynthesis of Polyketides in Heterologous Hosts. *Microbiol. Mol. Biol. Rev* 65, 106–118 (2001). [PubMed: 11238987]
3. Xue Q, Ashley G, Hutchinson CR & Santi DV A multiplasmid approach to preparing large libraries of polyketides. *Proc. Natl. Acad. Sci. U. S. A* 96, 11740–11745 (1999). [PubMed: 10518520]
4. Gokhale RS, Sankaranarayanan R & Mohanty D Versatility of polyketide synthases in generating metabolic diversity. *Curr. Opin. Struct. Biol* 17, 736–743 (2007). [PubMed: 17935970]
5. Dunn BJ & Khosla C Engineering the acyltransferase substrate specificity of assembly line polyketide synthases. *J. R. Soc. Interface* 10, 20130297 (2013). [PubMed: 23720536]
6. Liu Q, Wu K, Cheng Y, Lu L, Xiao E, Zhang Y, Deng Z & Liu T Engineering an iterative polyketide pathway in *Escherichia coli* results in singleform alkene and alkane overproduction. *Metab. Eng* 28, 82–90 (2015). [PubMed: 25536488]
7. Cai W & Zhang W Engineering modular polyketide synthases for production of biofuels and industrial chemicals. *Curr. Opin. Biotechnol* 50, 32–38 (2018). [PubMed: 28946011]
8. Menendez-Bravo S, Comba S, Sabatini M, Arbolaza A & Gramajo H Expanding the chemical diversity of natural esters by engineering a polyketide-derived pathway into *Escherichia coli*. *Metab. Eng* 24, 97–106 (2014). [PubMed: 24831705]

9. Rodriguez E, Menzella HG & Gramajo H Chapter 15 Heterologous Production of Polyketides in Bacteria. *Methods in Enzymology* 459, (Elsevier Inc., 2009).
10. Kealey JT, Liu L, Santi DV, Betlach MC & Barr PJ Production of a polyketide natural product in nonpolyketide-producing prokaryotic and eukaryotic *hosts*. *Proc. Natl. Acad. Sci. U. S. A* 95, 505–509 (1998). [PubMed: 9435221]
11. Pfeifer BA, Admiraal SJ, Gramajo H, Cane DE & Khosla C Biosynthesis of complex polyketides in a metabolically engineered strain of *E. coli*. *Science* 291, 1790–1792 (2001). [PubMed: 11230695]
12. Menendez-Bravo S, Roulet J, Sabatini M, Comba S, Dunn R, Gramajo H & Arbolaza A High cell density production of multimethyl-branched long-chain esters in *Escherichia coli* and determination of their physicochemical properties. *Biotechnol. Biofuels* 9, 215 (2016). [PubMed: 27757170]
13. Smanski MJ, Zhou H, Claesen J, Shen B, Fischbach M & Voigt CA Synthetic biology to access and expand nature's chemical diversity. *Nat Rev Microbiol* 14, 135–149 (2016). [PubMed: 26876034]
14. Stevens DC, Hari TPA & Boddy CN The role of transcription in heterologous expression of polyketides in bacterial hosts. *Nat. Prod. Rep* 30, 1391–1411 (2013). [PubMed: 24061690]
15. Fujii I Heterologous expression systems for polyketide synthases. *Nat. Prod. Rep* 26, 155–169 (2009). [PubMed: 19177221]
16. Ducat DC, Way JC & Silver PA Engineering cyanobacteria to generate high-value products. *Trends Biotechnol.* 29, 95–103 (2011). [PubMed: 21211860]
17. Rubin BE, Wetmore KM, Price MN, Diamond S, Shultzaberger RK, Lowe LC, Curtin G, Arkin AP, Deutschbauer A & Golden SS The essential gene set of a photosynthetic organism. *Proc. Natl. Acad. Sci. U. S. A* 112, E6634–E6643 (2015). [PubMed: 26508635]
18. Diamond S, Jun D, Rubin BE & Golden SS The circadian oscillator in *Synechococcus elongatus* controls metabolite partitioning during diurnal growth. *Proc. Natl. Acad. Sci. U. S. A.* 112, E1916–E1925 (2015). [PubMed: 25825710]
19. Vijayan V, Jain IH & O'Shea EK A high resolution map of a cyanobacterial transcriptome. *Genome Biol.* 12, R47 (2011). [PubMed: 21612627]
20. Broddrick JT, Rubin BE, Welkiec DG, Dud N, Mihf N, Diamond S, Lee JJ, Golden SS & Palsson BO Unique attributes of cyanobacterial metabolism revealed by improved genome-scale metabolic modeling and essential gene analysis. *Proc. Natl. Acad. Sci. U. S. A* 113, E8344–E8353 (2016). [PubMed: 27911809]
21. Taton A, Unglaub F, Wright NE, Zeng WY, Paz-Yepes J, Brahamsha B, Palenik B., Peterson TC, Haerizadeh F, Golden SS & Golden JW Broad-host-range vector system for synthetic biology and biotechnology in cyanobacteria. *Nucleic Acids Res.* 42, e136 (2014). [PubMed: 25074377]
22. Ma AT, Schmidt CM & Golden JW Regulation of gene expression in diverse cyanobacterial species by using theophylline-responsive riboswitches. *Appl. Environ. Microbiol* 80, 6704–6713 (2014). [PubMed: 25149516]
23. Ruffing AM Engineered cyanobacteria: Teaching an old bug new tricks. *Bioeng. Bugs* 2, 136–149 (2011). [PubMed: 21637004]
24. Atsumi S, Higashide W & Liao JC Direct photosynthetic recycling of carbon dioxide to isobutyraldehyde. *Nat. Biotechnol* 27, 1177–1180 (2009). [PubMed: 19915552]
25. Ducat DC, Avelar-Rivas JA, Way JC & Silvera PA Rerouting carbon flux to enhance photosynthetic productivity. *Appl. Environ. Microbiol* 78, 2660–2668 (2012). [PubMed: 22307292]
26. Videau P, Wells KN, Singh AJ, Gerwick WH & Philmus B Assessment of *Anabaena sp.* strain PCC 7120 as a heterologous expression host for cyanobacterial natural products: production of lyngbyatoxin A. *ACS Synth. Biol* 5, 978–988 (2016). [PubMed: 27176641]
27. Knoot CJ, Ungerer JL, Wangikar PP & Pakrasi HB Cyanobacteria: promising biocatalysts for sustainable chemical production. *J. Biol. Chem* jbc.R117.815886 (2017).
28. Golden SS & Sherman LA A hybrid plasmid is a stable cloning vector for the cyanobacterium *Anacystis nidulans* R2. *J. Bacteriol* 155, 966–972 (1983). [PubMed: 6309751]

29. Chen Y, Taton A, Go M, London RE, Pieper LM, Golden SS & Golden JW. Self-replicating shuttle vectors based on pANS, a small endogenous plasmid of the unicellular cyanobacterium *Synechococcus elongatus* PCC 7942. *Microbiol. (United Kingdom)* 162, 2029–2041 (2016).
30. Clerico EM, Ditty JL & Golden SS Specialized techniques for site-directed mutagenesis in cyanobacteria. *Methods Mol. Biol* 362, 155–171 (2007). [PubMed: 17417008]
31. Rippka R, Deruelles J, Waterbury JB, Herdman M & Stanier RY Generic assignments, strain histories and properties of pure cultures of cyanobacteria. *Microbiology* 111, 1–61 (1979).
32. Chin JX, Chung BKS & Lee DY Codon Optimization OnLine (COOL): A web-based multi-objective optimization platform for synthetic gene design. *Bioinformatics* 30, 2210–2212 (2014). [PubMed: 24728853]
33. Bligh EG & Dyer WJ A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol* 37, 911–917 (1959). [PubMed: 13671378]
34. Beld J, Sonnenschein EC, Vickery CR, Noel JP & Burkart MD The phosphopantetheinyl transferases: catalysis of a post-translational modification crucial for life. *Nat. Prod. Rep* 31, 61–108 (2014). [PubMed: 24292120]
35. Chan YA, Podevels AM, Kevany BM & Thomas MG Biosynthesis of polyketide synthase extender units. *Nat. Prod. Rep* 26, 90–114 (2009). [PubMed: 19374124]
36. Hughes AJ & Keatinge-Clay A Enzymatic extender unit generation for in vitro polyketide synthase reactions: Structural and functional showcasing of *Streptomyces coelicolor* *MatB*. *Chem. Biol* 18, 165–176 (2011). [PubMed: 21338915]
37. Dayem LC, Carney JR, Santi DV, Pfeifer BA, Khosla C & Kealey JT Metabolic engineering of a methylmalonyl-CoA mutase - epimerase pathway for complex polyketide biosynthesis in *Escherichia coli*. *Biochemistry* 41, 5193–5201 (2002). [PubMed: 11955068]
38. Diacovich L, Peirú S, Kurth D, Rodríguez E, Podestá F, Khosla C & Gramajo H Kinetic and structural analysis of a new group of acyl-CoA carboxylases found in *Streptomyces coelicolor* A3(2). *J. Biol. Chem* 277, 31228–31236 (2002). [PubMed: 12048195]
39. Begemann MB, Begemann MB, Zess EK, Walters EM, Schmitt EF, Markley AL & Pflieger BF An organic acid based counter selection system for cyanobacteria. *PLoS One* 8, e76594 (2013). [PubMed: 24098537]
40. Van der Plas J, Oosterhoff-Teertstra R, Borrias M & Weisbeek P Identification of replication and stability functions in the complete nucleotide sequence of plasmid pUFI24 from the cyanobacterium *Synechococcus sp.* PCC 7942. *Mol. Microbiol* 6, 653–664 (1992). [PubMed: 1552863]
41. Elledge SJ & Davis RW Position and density effects on repression by stationary and mobile DNA-binding proteins. *Genes Dev* 3, 185–197 (1989). [PubMed: 2523839]
42. Li R & Golden SS Enhancer activity of light-responsive regulatory elements in the untranslated leader regions of cyanobacterial *psbA* genes. *Proc. Natl. Acad. Sci. U. S. A* 90, 11678–11682 (1993). [PubMed: 8265608]
43. Wang B, Wang J & Meldrum DR Application of synthetic biology in cyanobacteria and algae. *Front. Microbiol* 3, 344 (2012). [PubMed: 23049529]
44. Kim WJ, Lee S-M, Um Y, Sim SJ & Woo HM Development of SyneBrick vectors as a synthetic biology platform for gene expression in *Synechococcus elongatus* PCC 7942. *Front. Plant Sci* 8, 293 (2017). [PubMed: 28303150]
45. Cao YQ, Li Q, Xia PF, Wei LJ, Guo N, Li JW & Wang SG AraBAD based toolkit for gene expression and metabolic robustness improvement in *Synechococcus elongatus*. *Sci. Rep* 7, 18059 (2017). [PubMed: 29273782]
46. Taton A, Ma AT, Ota M, Golden SS & Golden JW NOT gate genetic circuits to control gene expression in cyanobacteria. *ACS Synth. Biol* 6, 2175–2182 (2017). [PubMed: 28803467]
47. Dubendorf JW & Studier FW Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with *Jac* repressor. *J. Mol. Biol* 219, 45–59 (1991). [PubMed: 1902522]
48. Huang HH, Camsund D, Lindblad P & Heidorn T Design and characterization of molecular tools for a synthetic biology approach towards developing cyanobacterial biotechnology. *Nucleic Acids Res* 38, 2577–2593 (2010). [PubMed: 20236988]

49. Quadri LEN, Weinreb PH, Lei M, Nakano MM, Zuber P & Walsh CT Characterization of Sfp, a *Bacillus subtilis* phosphopantetheinyl transferase for peptidyl carrier protein domains in peptide synthetases. *Biochemistry* 37, 1585–1595 (1998). [PubMed: 9484229]
50. Shih PM, Wu D, Latifi A, Axen SD, Fewer DP, Talla E, Calteau A, Cai F, Tandeau de Marsac N, Rippka R, Herdman M, Sivonen K, Coursin T, Laurent T, Goodwin L, Nolan M, Davenport KW, Han CS, Rubin EM, Eisen JA, Woyke T, Gugger M & Kerfeld CA Improving the coverage of the cyanobacterial phylum using diversity-driven genome sequencing. *Proc. Natl. Acad. Sci. U. S. A* 110, 1053–1058 (2013). [PubMed: 23277585]
51. Calteau A, Fewer DP, Latifi A, Coursin T, Laurent T, Jokela J, Kerfeld CA, Sivonen K, Piel J & Gugger M Phylum-wide comparative genomics unravel the diversity of secondary metabolism in Cyanobacteria. *BMC Genomics* 15, 977 (2014). [PubMed: 25404466]
52. Yang G, Zhang Y, Lee NK, Cozad MA, Kearney SE, Luesch H & Ding Y Cyanobacterial Sfp-type phosphopantetheinyl transferases functionalize carrier proteins of diverse biosynthetic pathways. *Sci. Rep* 7, 11888 (2017). [PubMed: 28928426]
53. Trivedi OA, Arora P, Vats A, Ansari MZ, Tickoo R, Sridharan V, Mohanty D & Gokhale RS Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. *Mol. Cell* 17, 631–643 (2005). [PubMed: 15749014]
54. La Clair JJ, Foley TL, Schegg TR, Regan CM & Burkart MD Manipulation of carrier proteins in antibiotic biosynthesis. *Chem. Biol* 11, 195–201 (2004). [PubMed: 15123281]
55. Ishikawa F, Haushalter RW & Burkart MD Dehydratase-specific probes for fatty acid and polyketide synthases. *J. Am. Chem. Soc* 134, 769–772 (2012). [PubMed: 22188524]
56. Cardinale S & Arkin AP Contextualizing context for synthetic biology - identifying causes of failure of synthetic biological systems. *Biotechnol. J* 7, 856–866 (2012). [PubMed: 22649052]
57. Temme K, Hill R, Segall-Shapiro TH, Moser F & Voigt CA Modular control of multiple pathways using engineered orthogonal T7 polymerases. *Nucleic Acids Res* 40, 8773–8781 (2012). [PubMed: 22743271]
58. Kehr JC, Picchi DG & Dittmann E Natural product biosyntheses in cyanobacteria: A treasure trove of unique enzymes. *Beilstein J. Org. Chem* 7, 1622–1635 (2011). [PubMed: 22238540]
59. Gomes ES, Schuch V & Lemos EG de M Biotechnology of polyketides: New breath of life for the novel antibiotic genetic pathways discovery through metagenomics. *Brazilian J. Microbiol* 44, 1007–1034 (2013).
60. Micallef ML, D'Agostino PM, Al-Sinawi B, Neilan B. a. & Moffitt MC Exploring cyanobacterial genomes for natural product biosynthesis pathways. *Mar. Genomics* 21, 1–12 (2015). [PubMed: 25482899]
61. Helfrich EJN, Reiter S & Piel J Recent advances in genome-based polyketide discovery. *Curr. Opin. Biotechnol* 29, 107–115 (2014). [PubMed: 24762576]




Figure 1: Modular-design of essential components for the production of PKS-derived compounds in *S. elongatus*.

Module I is responsible for the biosynthesis of the carboxyacyl-CoA precursors using three different routes: module IA contains *matB* and *epi* genes encoding for an acyl-CoA synthetase and epimerase, respectively; module IB contains *mutA*, *mutB* (encoding for the methylmalonyl-CoA mutase complex), and *epi* genes; module IC contains *accA2*, *pccE*, and *pccB* genes (encoding for the propionyl-CoA carboxylase complex). Module II is responsible for the post-translational modification of the PKS and the controlled orthogonal expression of the PKS gene cluster using two T7 RNAP expression devices. In module IIA, the T7 RNAP is expressed from the synthetic *E. coli* consensus conII promoter (P_{conII}) with riboswitch F (rswF); in module IIB the T7 RNAP is expressed from a weakened version of the conII promoter (P_{conII}^*) with riboswitch B (rswB). In both modules, the *sfp* gene encoding for the phosphopantetheinyl transferase is expressed from the conII promoter with riboswitch F (rswF). Module III is responsible for the biosynthesis of the PKS-derived products, in this case, the mycobacterial PKS MAS pathway that includes *papA5* (polyketide-associated protein A5), *fadD28* (acyl-AMP ligase) and *mas* (mycocerosic acid synthase) genes. These genes were engineered in a single operon expressed from P_{T7} .




Figure 2: Characterization of T7 RNAP expression devices in *S. elongatus*.

(a) Scheme of the theophylline-regulated T7 RNAP expression circuits. The expression of the T7 RNAP was driven by a mutated P_{conII} ($P_{conII}^{(*)}$) with lower activity and was translationally controlled by (b) riboswitch F ($P_{conII}^{(*)}$ -rswF-*T7RNAP*/ P_{T7} -yfp) or (c) riboswitch B ($P_{conII}^{(*)}$ -rswB-*T7RNAP*/ P_{T7} -yfp). YFP-reporter fluorescence served as an easily readable output. Three independent clones were analyzed for each construct (represented with different shades of grey) and error bars indicate standard deviations of three replicates of the experiment.




Figure 3: PPTase *in vitro* assays.

Sfp functional *in vitro* assay by detection of *E. coli* ACP phosphopantetheinylation with fluorescently labeled CoA (TAMRA-CoA). Proteins were separated by SDS-PAGE and visualized by UV fluorescence. Lanes: 1, purified *E. coli* ACP plus TAMRA-CoA and purified Sfp (positive control); 2, purified *E. coli* ACP (negative control); 3, 4, 5, purified *E. coli* ACP plus TAMRA-CoA and soluble protein extracts from three independent clones from strain JR102; 6, purified *E. coli* ACP plus TAMRA-CoA and protein extract from strain JR104; 7, purified *E. coli* ACP plus TAMRA-CoA and wild-type *S. elongatus* protein extract (negative control).




Figure 4. Functional analysis of modules IA, II (A and B), and III.

(a) Scheme of the full pathways for MBE biosynthesis using module IA for (2S)-methylmalonyl-CoA production. (b) Radio-TLC analysis of total lipid fraction from *S. elongatus* strain JR101: lanes 1, 2, 3, 4, 5, 6; JR103 (without module III): lane 7; and from *E. coli* RQ1 MBE producer strain: lane 8. The lipid fractions on lanes 1, 2, and 3, were each extracted from one of three cultures grown from three independent clones as biological replicates. These cultures were supplemented with methylmalonate and *n*-octanol, while *E. coli* RQ1 was supplemented with propionate and *n*-octanol for the bioconversion assay. The cultures used for lanes 4, 5, and 6 were grown from the same clone as for lane 1 but in the absence of one or both precursors, *n*-octanol and methylmalonate, as indicated below each lane. (c) Radio-TLC analysis of total lipid fraction from *S. elongatus* strain JR102: lanes 1, 2, 3, 4, 5, 6; JR104 (without module III): lane 7; wild-type strain AMC2302: lane 8, and from *E. coli* RQ1 MBE producer strain: lane 9. The lipid fractions on lanes 1, 2, and 3 were

each extracted from one of three cultures grown from three independent clones as biological replicates. These cultures were supplemented with methylmalonate and *n*-octanol, while *E. coli* RQ1 culture was supplemented with propionate and *n*-octanol for the bioconversion assay. The cultures used for lanes 4, 5, and 6 were grown from the same clone as for lane 1 but in the absence of either or both precursors, *n*-octanol and methylmalonate, as indicated below each lane. Modules analyzed are indicated on the left of each TLC and each color of the boxes makes reference to the colors used in Fig. 1 for each module. MBE, multimethyl-branched wax esters. Spots that are not annotated were not analyzed by LC/MS. A comparison of the pattern shows that their presence is independent of the modules. The second spot, from top to down, appears only when *n*-octanol was supplemented to the media.




Figure 5. Functional analysis of module IC.

(a) Scheme of full pathways for MBE biosynthesis using module IC for (2S)-methylmalonyl-CoA production. (b) Radio-TLC analysis of total lipid fraction from *S. elongatus* strain JR107: lanes 1, 2, 3, 4, 5 and *E. coli* RQ1 MBE producer strain: lane 6. The lipid fractions on lanes 1, 4, and 5 were each extracted from one of three cultures grown from three independent clones as biological replicates. These cultures and the *E. coli* RQ1 culture were supplemented with propionate and *n*-octanol for the bioconversion assay. The cultures used for lanes 2 and 3 were grown from the same clone as for lane 1 but in the absence of one or both precursors, *n*-octanol and propionate, as indicated below each lane. (c) Radio-TLC analysis of total lipid fraction from *S. elongatus* strain JR108: lanes 1, 2, 3, 5, 6, wild-type strain AMC2302: lane 4 and *E. coli* RQ1 MBE producer strain: lane 7. The lipid fractions on lanes 1, 5, and 6 were each extracted from one of three cultures grown from three independent clones as biological replicates. These cultures and the *E. coli* RQ1 culture were supplemented with propionate and *n*-octanol for the bioconversion assay. The cultures

used for lanes 2 and 3 were grown from the same clone as for lane 1 but in the absence of either or both precursors, *n*-octanol and propionate, as indicated below each lane. Modules analyzed are indicated on the left of each TLC and each color of the boxes makes reference to the colors used in Fig. 1 for each module. MBE, multimethyl-branched wax esters.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6. MBE biosynthesis by JR101 and JR102 cyanobacterial strains induced with different theophylline concentrations.

(a) Radio-TLC analysis of the total lipid fraction from *S. elongatus* strain JR101 induced with theophylline (0, 0.5, 1, 2, 4, 8 mM) and supplemented with methylmalonate (10 mM) and *n*-octanol (0.25 mM) for the bioconversion assay; and of the total lipid fraction from the *E. coli* RQ1 MBE producer strain, used as MBE standard, supplemented with propionate (30 mM) and *n*-octanol (0.5 mM). (b) Radio-TLC analysis of the total lipid fraction from *S. elongatus* strain JR102 induced with theophylline (0, 0.5, 1, 2, 4, 8 mM) and supplemented

with methylmalonate (10 mM) and *n*-octanol (0.25 mM); of the total lipid fraction from wild-type *S. elongatus* strain induced with theophylline (2 mM), and supplemented as above with *n*-octanol and methylmalonate; and of the total lipid fraction from *E. coli* RQ1 with propionate and *n*-octanol supplied as above. Modules analyzed are indicated on the left of each TLC and each color of the boxes makes reference to the colors used in Fig. 1 for each module. MBE, multimethyl-branched wax esters.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Plasmids developed

Plasmid	Description	Antibiotic resistance	Reference
pJR03	pANS- <i>aadA</i> -P _{conII} - <i>matB</i>	Sp Sm	This work
pJR04	NS2TC- <i>aphI</i> -P _{conII} - <i>epimerase</i>	Tc Km	This work
pJR05	pAUS- <i>aadA</i> -P _{conII} - <i>mutA</i> - <i>mutB</i>	Sp Sm	This work
pJR06	pANS- <i>aadA</i> -P _{conII} - <i>accA2</i> - <i>pccE</i> - <i>pccB</i>	Sp Sm	This work
pJR07	NS1- <i>natI</i> -P _{T7} - <i>papA5</i> - <i>fadD28</i> - <i>mas</i>	Nt	This work
pJR08	NS3- <i>aacCI</i> -P _{conII} - <i>rswF</i> - <i>sfp</i> -P _{conII} - <i>rswF</i> - <i>T7RNAP</i>	Gm	This work
pJR09	NS3- <i>aacCI</i> -P _{conII} - <i>rswF</i> - <i>sfp</i> -P _{conII*} - <i>rswB</i> - <i>T7RNAP</i>	Gm	This work
pAM5467	NS2TC- <i>aacCI</i> -P _{T7} - <i>yfp</i>	Gm	This work
pAM5470	NS1- <i>aadA</i> -P _{conII*} - <i>rswB</i> - <i>T7RNAP</i>	Sp Sm	This work
pAM5471	NS1- <i>aadA</i> -P _{conII*} - <i>rswF</i> - <i>T7RNAP</i>	Sp Sm	This work

Table 2.

S. elongatus strains

Strain	Genotype	Antibiotic resistance	Reference
AMC2302	<i>S. elongatus</i> PCC 7942 WT strain cured of the small pANS plasmid	-	52
JR101	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>matB</i> ; NS2TC:: <i>aphI</i> -P _{conII} - <i>epimerase</i> ; NS1:: <i>natI</i> -P _{T7} - <i>papA5-fadD28-mas</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswF-T7RNAP</i>	Sp Sm Km Nt Gm	This work
JR102	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>matB</i> ; NS2TC:: <i>aphI</i> -P _{conII} - <i>epimerase</i> ; NS1:: <i>natI</i> -P _{T7} - <i>papA5-fadD28-mas</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswB-T7RNAP</i>	Sp Sm Km Nt Gm	This work
JR103	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>matB</i> ; NS2TC:: <i>aphI</i> -P _{conII} - <i>epimerase</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswF-T7RNAP</i>	Sp Sm Km Gm	This work
JR104	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>matB</i> ; NS2TC:: <i>aphI</i> -P _{conII} - <i>epimerase</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswB-T7RNAP</i>	Sp Sm Km Gm	This work
JR105	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>mutA-mutB</i> ; NS2TC:: <i>aphI</i> -P _{conII} - <i>epimerase</i> ; NS1:: <i>natI</i> -P _{T7} - <i>papA5-fadD28-mas</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswF-T7RNAP</i>	Sp Sm Km Nt Gm	This work
JR106	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>mutA-mutB</i> ; NS2TC:: <i>aphI</i> -P _{conII} - <i>epimerase</i> ; NS1:: <i>natI</i> -P _{T7} - <i>papA5-fadD28-mas</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswB-T7RNAP</i>	Sp Sm Km Nt Gm	This work
JR107	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>accA2-pccE-pccB</i> ; NS1:: <i>natI</i> -P _{T7} - <i>papA5-fadD28-mas</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswF-T7RNAP</i>	Sp Sm Nt Gm	This work
JR108	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>accA2-pccE-pccB</i> ; NS1:: <i>natI</i> -P _{T7} - <i>papA5-fadD28-mas</i> ; NS3:: <i>aacCI</i> -P _{conII} - <i>rswF-sfp</i> -P _{conII} - <i>rswB-T7RNAP</i>	Sp Sm Nt Gm	This work
JR109	AMC2302; pANS- <i>aadA</i> -P _{conII} - <i>accA2-pccE-pccB</i>	Sp Sm	This work
JR110	AMC2302; NS1:: <i>aadA</i> -P _{conII} - <i>rswB-T7RNAP</i> ; NS2:: <i>aacCI</i> -P _{T7} - <i>yfp</i>	Sp Sm Gm	This work
JR111	AMC2302; NS1:: <i>aadA</i> -P _{conII} - <i>rswF-T7RNAP</i> ; NS2:: <i>aacCI</i> -P _{T7} - <i>yfp</i>	Sp Sm Gm	This work